RPID RAPID MICRO BIOSYSTEMS INC

Rapid Micro Biosystems to Announce Third Quarter 2023 Financial Results on November 3, 2023

Rapid Micro Biosystems to Announce Third Quarter 2023 Financial Results on November 3, 2023

LOWELL, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2023 financial results prior to the market open on Friday, November 3, 2023.

In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 3, 2023. The live webcast will be accessible on the Company’s website and will be available for replay for one year from the webcast date.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit or follow the company on Twitter at or on .



Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
 

Media Contact:
 
EN
19/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPID MICRO BIOSYSTEMS INC

 PRESS RELEASE

Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

Rapid Micro Biosystems Reports First Quarter 2025 Financial Results Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma (“MilliporeSigma”). Reaffirms fu...

 PRESS RELEASE

Rapid Micro Biosystems to Announce First Quarter 2025 Financial Result...

Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025 LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m...

 PRESS RELEASE

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listin...

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units (“RSUs”) of the Company’s Class A common stock (“Common Stock”) as a material inducement to employment of one new employee and ...

 PRESS RELEASE

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Finan...

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023.Announces full year 2024 total revenue of $28.1 million, representing 25% growth compared to 2023; recurring revenue increase by 14% compared to 2023.Reports record fourth quarter gross margin of 12%, representing a 15-percentage point improvement over the fourth quarter of 2023; full year...

 PRESS RELEASE

Rapid Micro Biosystems Announces Global Distribution and Collaboration...

Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development. LEXINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch